Literature DB >> 9062689

SA4503, a novel cognitive enhancer, with sigma 1 receptor agonistic properties.

K Matsuno1, T Senda, T Kobayashi, K Okamoto, K Nakata, S Mita.   

Abstract

We found a potent and selective sigma 1 (sigma 1) receptor ligand, SA4503 (1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride). This compound had a high affinity for sigma 1 receptor subtype (IC50 = 17 +/- 1.9 nM), but a low affinity for sigma 2 receptor subtype (IC50 = 1800 +/- 310 nM). The present study examines the effect of this compound on the central cholinergic functions, since sigma receptor has been reported to interact with the central cholinergic neurons. SA4503 elicited the increase in extracellular acetylcholine level in rat frontal cortex, while it did not affect the striatal acetylcholine level. On the other hand, tetrahydroaminoacridine (THA), an acetylcholinesterase (AChE) inhibitor, increased the extracellular acetylcholine level in both regions. Although both compounds had anti-amnesic effect against scopolamine-induced memory impairment, THA also induced catalepsy in rats. These results suggest that SA4503 may be a novel cognitive enhancer, with sigma 1 receptor agonistic properties. In addition, SA4503 does not cause striatal cholinomimetic side-effects, which is different from THA.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9062689     DOI: 10.1016/s0166-4328(97)86074-3

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  12 in total

Review 1.  Sigma receptors: biology and therapeutic potential.

Authors:  Xavier Guitart; Xavier Codony; Xavier Monroy
Journal:  Psychopharmacology (Berl)       Date:  2004-06-10       Impact factor: 4.530

2.  Sigma 1 receptor subtype is involved in the facilitation of cortical dopaminergic transmission in the rat brain.

Authors:  T Kobayashi; K Matsuno; M Murai; S Mita
Journal:  Neurochem Res       Date:  1997-09       Impact factor: 3.996

3.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

4.  The attenuation of learning impairments induced after exposure to CO or trimethyltin in mice by sigma (sigma) receptor ligands involves both sigma1 and sigma2 sites.

Authors:  T Maurice; V L Phan; Y Noda; K Yamada; A Privat; T Nabeshima
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

Review 5.  Roles of sigma-1 receptors in Alzheimer's disease.

Authors:  Jia-Li Jin; Min Fang; Yan-Xin Zhao; Xue-Yuan Liu
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  Cutamesine Overcomes REM Sleep Deprivation-Induced Memory Loss: Relationship to Sigma-1 Receptor Occupancy.

Authors:  Nisha K Ramakrishnan; Marianne Schepers; Gert Luurtsema; Csaba J Nyakas; Philip H Elsinga; Kiichi Ishiwata; Rudi A J O Dierckx; Aren van Waarde
Journal:  Mol Imaging Biol       Date:  2015-06       Impact factor: 3.488

7.  Anti-amnesic effect of dimemorfan in mice.

Authors:  Hui-Hung Wang; Jyh-Wei Chien; Yueh-Ching Chou; Jyh-Fei Liao; Chieh-Fu Chen
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

8.  Regional differences of the effect of sigma receptor ligands on the acetylcholine release in the rat brain.

Authors:  T Kobayashi; K Matsuno; S Mita
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

9.  Involvement of the sigma1 (sigma1) receptor in the anti-amnesic, but not antidepressant-like, effects of the aminotetrahydrofuran derivative ANAVEX1-41.

Authors:  J Espallergues; P Lapalud; A Christopoulos; V A Avlani; P M Sexton; A Vamvakides; T Maurice
Journal:  Br J Pharmacol       Date:  2007-08-06       Impact factor: 8.739

10.  A Role for Sigma Receptors in Stimulant Self Administration and Addiction.

Authors:  Jonathan L Katz; Tsung-Ping Su; Takato Hiranita; Teruo Hayashi; Gianluigi Tanda; Theresa Kopajtic; Shang-Yi Tsai
Journal:  Pharmaceuticals (Basel)       Date:  2011
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.